SEMA 10 mg Vial

Semaglutide is a synthetic GLP-1 receptor agonist that mimics the action of the endogenous glucagon-like peptide-1 hormone. It works by:

• Stimulating Insulin Release: Enhances glucose-dependent insulin secretion from the pancreas, lowering blood sugar levels.
• Suppressing Glucagon Release: Reduces glucagon secretion, which decreases hepatic glucose production.
• Reducing Appetite: Acts on brain receptors to increase satiety, reducing hunger and caloric intake.
• Slowing Gastric Emptying: Delays the movement of food from the stomach to the small intestine, promoting prolonged feelings of fullness.
  These actions collectively support weight loss, improved glycemic control, and reduced cardiovascular and kidney risks.

• Semaglutide: 20 mg per vial or specified concentration.
• Inactive Ingredients (may vary by formulation): Disodium phosphate dihydrate, sodium chloride, water for injection, hydrochloric acid or sodium hydroxide (for pH adjustment), and, for sublingual formulations, an absorption enhancer like SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate).

• Refrigerate unopened vials (36°F to 46°F; 2°C to 8°C). Do not freeze.
• After first use, store at room temperature (59°F to 86°F; 15°C to 30°C) or refrigerated for up to 56 days.
• Protect from excessive heat and sunlight. Discard if the solution is cloudy, discolored, or contains particles.
• Use a new needle for each injection and dispose of needles safely in a sharps container.

Clinical trials (e.g., STEP and SUSTAIN programs) have demonstrated that Semaglutide, at doses up to 2.4 mg weekly, achieves:

• Weight Loss: Up to 15–20% body weight reduction in obese or overweight adults after 68 weeks, when combined with lifestyle changes.
• Glycemic Control: Significant reductions in HbA1c (1–2%) in type 2 diabetes patients.
• Cardiovascular Benefits: 20% lower risk of major adverse cardiovascular events in patients with type 2 diabetes and heart disease.
• Kidney Protection: Reduced progression of chronic kidney disease in patients with type 2 diabetes.
  Note: Efficacy for compounded 20 mg formulations depends on accurate dosing and adherence to medical guidance.

Compounded Semaglutide is not FDA-approved, and its safety and efficacy have not been evaluated by the FDA. Use only under the supervision of a qualified healthcare provider. Always consult your doctor to ensure this product is appropriate for your medical condition and to discuss potential risks and benefits.